Antibodies News and Research

RSS

COVID-19 vaccine INO-4800 shows efficacy against SARS-CoV-2 variants

Researchers in the United States have demonstrated the efficacy of the vaccine INO-4800 against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

15 Apr 2021

New machine learning method for designing more effective antibody drugs

Antibodies are not only produced by our immune cells to fight viruses and other pathogens in the body. For a few decades now, medicine has also been using antibodies produced by biotechnology as drugs.

15 Apr 2021

CHOP researchers identify key target responsible for treatment failure in patients with hemophilia A

Researchers at Children's Hospital of Philadelphia have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A.

15 Apr 2021

Ovarian follicular function unaffected by SARS-CoV-2 infection or Pfizer vaccine, study finds

A new study by researchers in Jerusalem indicates that while specific antibodies to the virus are present in both serum and ovarian follicles following infection or vaccination, there is no apparent adverse effect on follicular function as a result.

15 Apr 2021

High antibody and inflammatory mediator levels may predict severe COVID-19

A new study reports on biomarkers could help predict the progression of the viral illness to dangerous levels early enough to enable timely intervention.

15 Apr 2021

Anti-diabetic drug phenformin may prompt stronger cancer-fighting activities

The anti-diabetic drug phenformin may prompt stronger cancer-fighting activities than its sister compound metformin, a finding that could have major implications for current and future clinical trials investigating both agents for their anti-cancer potential, according to researchers at Massachusetts General Hospital (MGH).

15 Apr 2021

Population-based study shows the persistence of neutralizing antibodies against coronavirus

It is an open question to what extent protection against reinfection persists after overcoming a SARS-CoV-2 infection.

15 Apr 2021

Self-assembling nanofibers can help limit damage caused by inflammatory diseases

Biomedical engineers at Duke University have developed a self-assembling nanomaterial that can help limit damage caused by inflammatory diseases by activating key cells in the immune system.

15 Apr 2021

Evidence of sustained immune responses weeks after Pfizer-BioNTech BNT162b2 vaccination

A new study published ahead of print in the Clinical Chemistry and Laboratory Medicine (CCLM) journal reports the production of a robust immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the Pfizer-BioNTech BNT162b2 vaccine. The increase in humoral immunity includes elevated Immunoglobulin G (IgG) and Immunoglobulin A (IgA) levels after the second mRNA dose.

14 Apr 2021

Updated Moderna vaccines neutralize South African SARS-CoV-2 variant in mice

Researchers in the United States have conducted a pre-clinical study demonstrating the efficacy of two updated versions of the Moderna mRNA-1273 vaccine against variants of severe acute respiratory syndrome coronavirus 2 – the agent that causes coronavirus disease 2019 (COVID-19).

14 Apr 2021

Study sheds light on reduced neutralization of SARS-CoV-2 variants of concern

Researchers in the United States have predicted the binding epitopes of uncharacterized neutralizing antibodies that target the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.

14 Apr 2021

Early monoclonal antibody therapies beneficial for COVID-19, finds study

A team of scientists recently conducted a large-scale study at Northwell Health, New York, USA, to evaluate the efficacy of neutralizing monoclonal antibody (MAB) therapies in preventing disease progression among patients with mild to moderate COVID-19. The findings reveal that the timing of initiating MAB therapy is a crucial factor in determining its efficacy against COVID-19.

14 Apr 2021

SARS-CoV-2 mutations impact T-cell recognition of virus

A new research paper posted to the bioRxiv preprint server deals with the impact of these mutations on adaptive cellular immunity.

14 Apr 2021

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.

14 Apr 2021

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

A new research paper posted to the medRxiv* preprint server describes the changes in genomic sequence observed during the course of infection in a patient on the drug tacrolimus, along with steroids, both potent immunosuppressants, and who also received convalescent plasma treatment. These mutations were observed to occur within three weeks from infection.

14 Apr 2021

No evidence B.1.1.7. variant worsens symptoms or increases risk of long COVID

The study, published in The Lancet, demonstrates that there is no evidence of a link between severe illness and death and lineage when comparing the B.1.1.7 lineage and other variants.

14 Apr 2021

Risk of E.R. visit or hospitalization 82% lower in mAbs-treated SARS-CoV-2 patients: Study

Recently, researchers from the U.S. reviewed electronic health records of SARS-CoV-2 patients at a medical center that started mAb infusions in January 2021 with the support of the National Disaster Medical System, part of the U.S. Department of Health and Human Services. The study is published on the preprint server, medRxiv.

14 Apr 2021

Researchers develop model for SARS-CoV-2 fusion intermediate that helps membrane fusion

The spike protein is the main part of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the infection. It consists of two subunits S1 and S2. Upon entry of the virus into the human body, the S1 subunit helps the virus bind to the angiotensin-converting enzyme 2 (ACE2) receptors on host cells.

13 Apr 2021

A host of mutations could compromise COVID-19 vaccines and antibody therapies

Researchers in the United States have identified 95 high-frequency mutations in the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that threaten to compromise the efficacy of current and future vaccines and antibody therapies for coronavirus disease 2019 (COVID-19).

13 Apr 2021

Alpaca nanobodies effective against South African SARS-CoV-2 variant

Researchers in South Africa and the UK have identified alpaca-derived nanoantibodies that potently neutralize variants of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

13 Apr 2021

Antibodies News and Research

COVID-19 vaccine INO-4800 shows efficacy against SARS-CoV-2 variants

New machine learning method for designing more effective antibody drugs

CHOP researchers identify key target responsible for treatment failure in patients with hemophilia A

Ovarian follicular function unaffected by SARS-CoV-2 infection or Pfizer vaccine, study finds

High antibody and inflammatory mediator levels may predict severe COVID-19

Anti-diabetic drug phenformin may prompt stronger cancer-fighting activities

Population-based study shows the persistence of neutralizing antibodies against coronavirus

Self-assembling nanofibers can help limit damage caused by inflammatory diseases

Evidence of sustained immune responses weeks after Pfizer-BioNTech BNT162b2 vaccination

Updated Moderna vaccines neutralize South African SARS-CoV-2 variant in mice

Study sheds light on reduced neutralization of SARS-CoV-2 variants of concern

Early monoclonal antibody therapies beneficial for COVID-19, finds study

SARS-CoV-2 mutations impact T-cell recognition of virus

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

No evidence B.1.1.7. variant worsens symptoms or increases risk of long COVID

Risk of E.R. visit or hospitalization 82% lower in mAbs-treated SARS-CoV-2 patients: Study

Researchers develop model for SARS-CoV-2 fusion intermediate that helps membrane fusion

A host of mutations could compromise COVID-19 vaccines and antibody therapies

Alpaca nanobodies effective against South African SARS-CoV-2 variant

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo